Skip to content

asancpt/BE-apps

Folders and files

NameName
Last commit message
Last commit date

Latest commit

6760e35 · Apr 13, 2020

History

24 Commits
Jan 28, 2019
Jan 22, 2019
Jan 28, 2019
Jan 28, 2019
Apr 12, 2020
Apr 12, 2020
Jan 28, 2019
Dec 26, 2018
Jan 22, 2019
Jan 26, 2019
Dec 26, 2018
Jan 28, 2019
Jan 28, 2019
Dec 31, 2018
Jan 28, 2019
Jan 26, 2019
Dec 26, 2018
Jan 28, 2019
Apr 13, 2020
Jan 28, 2019
Jan 28, 2019
Jan 28, 2019
Apr 12, 2020
Jan 28, 2019
Dec 26, 2018
Dec 26, 2018
Jan 26, 2019
Dec 26, 2018
Dec 26, 2018

Repository files navigation

Introduction

To assess bioequivalence, the 90% confidence interval for the difference in the means of the log-transformed data should be calculated using appropriate methods to the study design. The antilogs (exponents) of the confidence limits obtained constitute the 90% confidence interval for the ratio of the geometric means between the T and R products. [@fda;@chow;@hauschke] To establish bioequivalence, the calculated confidence interval should fall within a bioequivalence limit, usually 80-125% for the ratio of the product averages. For nonreplicated crossover designs, general linear model procedures available in PROC GLM in SAS are preferred, although linear mixed-effects model procedures can also be indicated for analysis. [@fda]

BE R package [@R-BE] can analyze bioequivalence study data with industrial strength. The current version of BE performs bioequivalency tests for several pharmacokinetic parameters of the conventional two-treatment, two-period, two-sequence (2x2) randomized crossover design. The statistical model includes factors accounting for the following sources of variation: sequence (SEQ), subjects nested in sequences (SUBJ(SEQ)), period (PRD), and treatment (TRT).

In this document, the author performed validation of bioequivalence tests performed by BE R package as compared to bioequivalence tests performed by PROC GLM or PROC MIXED in SAS.

Poster

Results

## $AUClast
## $AUClast$`Analysis of Variance (log scale)`
##                          SS DF           MS           F            p
## SUBJECT        2.875497e+00 32 8.985928e-02 3.183942248 0.0008742828
## GROUP          1.024607e-01  1 1.024607e-01 1.145416548 0.2927731856
## SUBJECT(GROUP) 2.773036e+00 31 8.945279e-02 3.169539016 0.0009544080
## PERIOD         3.027399e-05  1 3.027399e-05 0.001072684 0.9740824428
## DRUG           3.643467e-02  1 3.643467e-02 1.290972690 0.2645764201
## ERROR          8.749021e-01 31 2.822265e-02          NA           NA
## TOTAL          3.786834e+00 65           NA          NA           NA
## 
## $AUClast$`Between and Within Subject Variability`
##                                 Between Subject Within Subject
## Variance Estimate                    0.03061507     0.02822265
## Coefficient of Variation, CV(%)     17.63193968    16.91883011
## 
## $AUClast$`Least Square Means (geometric mean)`
##                 Reference Drug Test Drug
## Geometric Means       5092.098  4858.245
## 
## $AUClast$`90% Confidence Interval of Geometric Mean Ratio (T/R)`
##                  Lower Limit Point Estimate Upper Limit
## 90% CI for Ratio    0.889436      0.9540753    1.023412
## 
## $AUClast$`Sample Size`
##                       True Ratio=1 True Ratio=Point Estimate
## 80% Power Sample Size            6                         7
## 
## 
## $Cmax
## $Cmax$`Analysis of Variance (log scale)`
##                          SS DF           MS           F          p
## SUBJECT        2.861492e+00 32 8.942162e-02 2.237604579 0.01367095
## GROUP          9.735789e-05  1 9.735789e-05 0.001054764 0.97429977
## SUBJECT(GROUP) 2.861394e+00 31 9.230304e-02 2.309706785 0.01131826
## PERIOD         4.717497e-03  1 4.717497e-03 0.118046317 0.73348258
## DRUG           6.837756e-03  1 6.837756e-03 0.171101730 0.68198228
## ERROR          1.238856e+00 31 3.996310e-02          NA         NA
## TOTAL          4.112258e+00 65           NA          NA         NA
## 
## $Cmax$`Between and Within Subject Variability`
##                                 Between Subject Within Subject
## Variance Estimate                    0.02616997      0.0399631
## Coefficient of Variation, CV(%)     16.28355371     20.1921690
## 
## $Cmax$`Least Square Means (geometric mean)`
##                 Reference Drug Test Drug
## Geometric Means       825.5206  808.8778
## 
## $Cmax$`90% Confidence Interval of Geometric Mean Ratio (T/R)`
##                  Lower Limit Point Estimate Upper Limit
## 90% CI for Ratio   0.9013625      0.9798396    1.065149
## 
## $Cmax$`Sample Size`
##                       True Ratio=1 True Ratio=Point Estimate
## 80% Power Sample Size            8                         8
## 
## 
## $Tmax
## $Tmax$`Wilcoxon Signed-Rank Test`
##   p-value 
## 0.2326894 
## 
## $Tmax$`Hodges-Lehmann Estimate`
##                            Lower Limit Point Estimate Upper Limit
## 90% Confidence Interval       -0.33000       -0.03500      0.1050
## 90% Confidence Interval(%)    74.37661       97.28237    108.1529

Plot

AUClast

Cmax

Tmax

References

sessionInfo()
## R version 3.6.3 (2020-02-29)
## Platform: x86_64-w64-mingw32/x64 (64-bit)
## Running under: Windows 10 x64 (build 17763)
## 
## Matrix products: default
## 
## locale:
## [1] LC_COLLATE=Korean_Korea.949  LC_CTYPE=Korean_Korea.949   
## [3] LC_MONETARY=Korean_Korea.949 LC_NUMERIC=C                
## [5] LC_TIME=Korean_Korea.949    
## 
## attached base packages:
## [1] stats     graphics  grDevices utils     datasets  methods   base     
## 
## other attached packages:
## [1] knitr_1.28
## 
## loaded via a namespace (and not attached):
##  [1] compiler_3.6.3  magrittr_1.5    tools_3.6.3     htmltools_0.4.0
##  [5] Rcpp_1.0.4.6    stringi_1.4.6   rmarkdown_2.1   stringr_1.4.0  
##  [9] xfun_0.12       digest_0.6.25   rlang_0.4.5     evaluate_0.14